Libor Havel

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Libor Havel

Oct 11, 2024, 14:37 | Insight

U.S. FDA approved nivolumab with platinum-doublet chemotherapy

Toni Choueiri shared a post on X: "JUST IN: US_FDA approved nivolumab with platinum-doublet chemotherapy…

Oct 4, 2024, 06:03 | Drugs

FDA approved Neoadjuvant/Adjuvant Nivolumab for resectable NSCLC

FDA Approval Introduces New Treatment Options for Adults with Resectable Lung Cancer Lacking Key Genetic…

Sep 2, 2024, 13:49 | Insight

Article of the day, September 2nd, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…

Aug 16, 2024, 14:13 | Insight

OS rates for IMpower133 and IMbrella A extension study in SCLC

Biagio Ricciuti shared a paper by Martin Reck et al. on X, adding: “Five-year survival…

Aug 14, 2024, 07:04 | Insight

ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study

Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper…

May 18, 2024, 09:06 | Blog

Jarushka Naidoo: Perioperative Nivolumab in Stage IIA-IIIB NSCLC

Jarushka Naidoo shared on X/Twitter: ''Ph III CM77T trial at NEJM: Perioperative Nivolumab in Stage…

May 18, 2024, 08:33 | Blog

Rami Manochakian: Results of Checkmate 77T trial of

Rami Manochakian shared a post on X/Twitter: ''Hot Off The Press. Just published at NEJM.…

All: 7 Posts: 1 - 100